The xenobiotic inhibitor profile of cytochrome P4502C8

British Journal of Clinical Pharmacology

Volumn 50, Issue 6, 2000, Pages 573-580

  Ong, Chin Eng ^c   Coulter, Sally ^a   Birkett, Donald J ^a   Ramana Bhasker, C ^a   Miners, John O ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

CYP2C8; Cytochrome P450; Cytochrome P450 inhibitors; Drug interactions

Indexed keywords

AMITRIPTYLINE; CLOTRIMAZOLE; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DIETHYLDITHIOCARBAMIC ACID; IMIDAZOLE; KETOCONAZOLE; OXIDOREDUCTASE; QUININE; TERFENADINE; TRIAZOLAM; TRIAZOLE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL CELL; ARTICLE; BACULOVIRUS; DRUG HYDROXYLATION; DRUG INHIBITION; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; LEPIDOPTERA; NONHUMAN; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

ANIMALS; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; BINDING, COMPETITIVE; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DITIOCARB; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; KINETICS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS; SPODOPTERA; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TRANSFECTION;

EID: 0034530753     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00316.x     Document Type: Article

References (39)

1. Cytochrome P4502C9: An enzyme of major importance in drug metabolism
2. Geographical/interracial differences in polymorphic drug oxidation
3. Flunitrazepam oxidative metabolism in human liver microsomes: Involvement of CYP2C19 and CYP3A4
4. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver mircrosomes
5. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
6. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
7. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P4502C8
8. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and P450 3A4 in human liver microsomes
9. Cytochrome P450 3A4 and 2C8 are involved in zopiclone metabolism
10. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation
11. Variability in human cytochrome P450 paclitaxel metabolism
12. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
13. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes
14. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, and 1A2: Regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes
15. A novel genetic polymorphism in the cytochrome P450 CYP2C8
16. In vitro approaches for the prediction of human drug metabolism
17. Baculovirus mediated expression of cytochrome P4502C8 and human NADPH-cytochrome P450 reductase: Optimisation of protein expression
18. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism
19. Torsenude metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes
20. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450
21. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
22. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
23. Comparative effects of the antimycotic drugs ketoconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes
24. Differential inhibition of CYP3A4 and CYP3A5 by antifungal agents
25. Mechanisms of inhibition of cytochrome P450 mediated drug oxidation by therapeutic agents
26. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolones
27. Effects of imidazole derivatives on cytochrome P450s of the IIIA family from human liver microsomes
28. Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non steroidal anti-inflammatory agents
29. Oxidation of midazolam and triazolam by by human liver cytochrome P450 IIIA4
30. Evidence for the involvement of CYP3A in the 3-hydroxylation of quinine
31. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase: Comparison to human liver microsomes and precision cut Tissue slices
32. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of predicted interaction with ketoconazole
33. Evidence of CYP3A4 mediated N-deethylation of amiodarone in human liver microsomal fractions
34. Cytochrome P450 mediating the N-demethylation of amitriptyline
35. Budesonide is metabolised by cytochrome P450, 3A (CYP3A) enzymes in human liver
36. Metabolism of cyclosporin
37. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms
38. Identification of the rabbit and human cytochromes P450 IIIA as the major enzymes involved in the N-demethylation of diltiazem
39. Lidocaine metabolism in human liver microsomes by cytochrome P450 IIIIA